Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature
Andrea Boutros(The University of Sydney), Carlo Genova(Ospedale Policlinico San Martino), Enrica T. Tanda(Ospedale Policlinico San Martino), Eleonora Arboscello(Ospedale Policlinico San Martino), Alberto Bottini(University of Genoa), R. Marconcini(Azienda Ospedaliera Universitaria Pisana), Giovanni Rossi(Ospedale Policlinico San Martino), Giuseppe Barletta(Ospedale Policlinico San Martino), P. Pronzato(Accademia Nazionale dei Lincei), Marina Grandis(Ospedale Policlinico San Martino), Elena Croce(Ospedale Policlinico San Martino), Marco Palla(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesco Spagnolo(Martin University), Paolo Fava, Mauro Ferrari(University of Pisa), Lucia Del Mastro(Ospedale Policlinico San Martino), F. De Rosa(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Matteo Lambertini(Ospedale Policlinico San Martino), Paolo Spallarossa(Ospedale Policlinico San Martino), A. Parisi(University of L'Aquila), Matteo Sarocchi(Ospedale Policlinico San Martino)
Cited by 21
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Cancer and fertility preservation: international recommendations from an expert meeting
|BMC Medicine|2016|779
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
|Annals of Oncology|2023|286
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282